Several compounds have demonstrated inhibitory activity toward anoctamin-1, including FDA-approved drugs (65, 73, 74), and chemical inhibition of anoctamin-1 has been shown to affect GIST cell proliferation and survival (65). The gene discussed is ANO1; the disease is gastrointestinal stromal tumor.